Pulmonary Arterial Hypertension Market

 

Key Highlights

 

  • The total prevalent cases of PAH in the 7MM were estimated to be approximately 87,713 cases in 2021, which are expected to increase by 2032.
  • According to DelveInsight estimates, in 2021, the total diagnosed prevalent cases of Pulmonary Arterial Hypertension were estimated to be approximately 52,628 in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019–2032).
  • Pulmonary Arterial Hypertension epidemiology is segmented as Total Pulmonary Arterial Hypertension Prevalent Cases, Total Pulmonary Arterial Hypertension Diagnosed Cases, Pulmonary Arterial Hypertension Age-specific Cases, Pulmonary Arterial Hypertension Class-specific Cases, Pulmonary Arterial Hypertension Gender-specific Cases, and Pulmonary Arterial Hypertension Subtype-specific Cases in the Pulmonary Arterial Hypertension market report.

 

Request for unlocking CAGR of Pulmonary Arterial Hypertension Market

 

DelveInsight’s ‘Pulmonary Arterial Hypertension - Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

The Pulmonary Arterial Hypertension market report provides current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted 7MM Pulmonary Arterial Hypertension market size from 2019 to 2032. The Report also covers current Pulmonary Arterial Hypertension treatment practice, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

 

Study Period: 2019–2032

pulmonary arterial hypertension market

Pulmonary Arterial Hypertension Market Disease: Understanding and Treatment Algorithm

Pulmonary Arterial Hypertension Overview

Pulmonary Hypertension (PH) is defined as mean pulmonary artery pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during exercise as measured by right heart catheterization. It is often characterized by a progressive and sustained increase in pulmonary vascular resistance (PVR) that eventually leads to right ventricular failure. It can be a life-threatening condition if untreated. The World Health Organization (WHO) has divided PH into five groups based on similarities in pathophysiology, clinical presentation, and therapeutic options. Of these PAH belongs to WHO Group 1.

 

PAH is a rare, progressive disorder characterized by hypertension in the pulmonary arteries for no apparent reason.  It was defined by the 6th World Symposium on Pulmonary Hypertension (WSPH) as a resting mean pulmonary artery pressure (mPAP) of 20 mm Hg or greater, a normal end-expiratory pulmonary artery wedge pressure (PAWP) less than or equal to 15 mm Hg, and a PVR of greater than or equal to 3 Wood units. PAH is further classified by the WHO into the following types: idiopathic PAH (IPAH), heritable PAH (HPAH), drug and toxin-induced PAH, and PAH associated with other diseases and disorders. The associated conditions include cirrhosis, HIV, congenital heart disease, and connective tissue diseases like scleroderma among others.

 

The initial symptom includes severe shortness of breath following exertion, including excessive fatigue, weakness, chest pain, dizzy spells, and fainting episodes. Hemoptysis, hypotension, and hoarseness due to compression of a nerve in the chest by an enlarged pulmonary artery are also observed. In advanced stages, syncope, tachypnea, cyanosis, and hypertrophy resulting in diminished functioning of the right portion of the heart are observed, often leading to right heart failure.

 

The most common form of PAH is idiopathic, characterized by elevated vascular resistance and pulmonary vasculature blood vessel constriction. It is considered that molecular and genetic factors, which result in the hypertrophy of smooth muscle, endothelial cells, and adventitia, are the root causes of restricted flow via pulmonary arteries, as seen in PAH.

 

The exact cause of PAH is unknown but in HPAH, an autosomal dominant genetic condition, mutations in the BMPR2 gene are the most common cause. PAH leads to disruption in one or more of three key pathways: nitric oxide (NO), prostacyclin (PGI2), thromboxane A2 (TXA2), and endothelin-1 (ET-1) leading to vasoconstriction, increased smooth muscle cell formation, inflammation, and thrombosis. These imbalances contribute to changes in the blood vessels, which further impact the progression of this disease.

 

Pulmonary Arterial Hypertension Diagnosis

Symptoms usually go unnoticed and may be present for up to 2 or 3 years before a diagnosis is made, often leading to misdiagnosis or a delay in early-stage diagnosis. While the global guidelines for PAH promote cardiac catheterization as the gold standard for diagnosis, transthoracic echocardiography is the most prevalent method of diagnosis.

 

Electrocardiogram (ECG), chest radiography, pulmonary function tests, and blood tests are also done to determine PAH. With improvement in disease understanding, biomarker-based assay and genetic testing are also being done to ascertain PAH. The Six-Minute Walk Test (6MWT) is also a widely used test to determine a patient's activity tolerance and estimated 1-year mortality.

Continued in the report…..

 

Pulmonary Arterial Hypertension Treatment

Treatment of patients with PAH is based on a patient's vasoreactivity test and functional capacity as determined by the WHO functional capacity classification. The goal is to increase vasodilation of the pulmonary vasculature and decrease PAP to increase CO.

 

The systematic step-by-step approach to managing PAH starts with general supportive care and progresses to focused pharmacological therapies. Individuals with PAH who respond to a vasoreactivity test performed during their RHC are treated with calcium channel blockers (CCB) such as nifedipine, diltiazem, and amlodipine.  Targeted monotherapy or combination treatments that combat the pathophysiology of the illness are the treatment choice for those who either do not meet the criteria for vasoreactivity testing or exhibit an insufficient response.

 

The current mainstay therapies that include PDE5 inhibitors, sGC stimulators, ERAs, prostacyclin analog, and agonists, for the treatment of PAH target the three major pathways, NO/cGMP, endothelin, and prostacyclin.

Continued in the report…..

 

Pulmonary Arterial Hypertension Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Pulmonary Arterial Hypertension, Total Diagnosed Cases of Pulmonary Arterial Hypertension, Age-specific Cases of Pulmonary Arterial Hypertension, Class-specific Cases of Pulmonary Arterial Hypertension, Gender-specific Cases of Pulmonary Arterial Hypertension, and Subtype-specific Cases of Pulmonary Arterial Hypertension scenario of Pulmonary Arterial Hypertension in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Key Findings

  • The total prevalent cases of PAH in the 7MM were estimated to be approximately 87,713 cases in 2021, which are expected to increase by 2032.
  • According to DelveInsight estimates, in 2021, the total diagnosed prevalent cases of Pulmonary Arterial Hypertension were estimated to be approximately 52,628 in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019–2032).
  • Among the 7MM, the United States accounted for nearly 58% of the total diagnosed prevalent cases of Pulmonary Arterial Hypertension in the 7MM in the year 2021, which are expected to increase further by 2032.
  • As per DelveInsight analysis, in EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Pulmonary Arterial Hypertension with approximately 5,065 in 2021, while Spain had the lowest diagnosed prevalent population of Pulmonary Arterial Hypertension with approximately 2,826 cases in 2021.
  • In 2021, the diagnosed prevalent population of Pulmonary Arterial Hypertension in Japan was found to be approximately 2,394 cases, which is expected to decrease during the study period of 2019–2032.
  • According to estimates based on DelveInsight’s epidemiology model for Pulmonary Arterial Hypertension, the gender distribution of the disease suggests a female predominance across the 7MM, with approximately 7,348 male and 23,193 female cases in the US in 2021.

Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Epidemiology

The epidemiology segment also provides the Pulmonary Arterial Hypertension epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Pulmonary Arterial Hypertension Drug Chapters

The drug chapter segment of the Pulmonary Arterial Hypertension report encloses a detailed analysis of Pulmonary Arterial Hypertension marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Pulmonary Arterial Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

 

Pulmonary Arterial Hypertension Marketed Drugs

Various therapies are approved for the treatment of PAH across FCs like UPTRAVI (selexipag), REMODULIN (treprostinil) (IV, SC), TYVASO (treprostinil, inhaled), ADEMPAS (riociguat), OPSUMIT (macitentan), ORENITRAM (treprostinil), and others.

 

UPTRAVI (selexipag): Johnson & Johnson/Nippon Shinyaku

UPTRAVI is a selective prostacyclin receptor agonist structurally distinct from prostacyclin. It is hydrolyzed by carboxylesterase 1 to yield an active metabolite more potent than selexipag. The prostacyclin receptor is one of the five major types of prostanoid receptors (IP, EP, DP, TP, and FP). In contrast to other prostanoid receptors, selexipag and its active metabolite are both selective for the prostacyclin receptor. Activation of the prostacyclin receptor induces vasodilation in pulmonary circulation and inhibits the proliferation of vascular smooth muscle cells, the key factor in PAH pathogenesis. Thus by dilating blood vessels in PAH individuals, selexipag decreases the pressure in the vessels supplying blood to the lungs.

 

Products detail in the report…

 

REMODULIN/ TREPROST (treprostinil): United Therapeutics/ Mochida Pharmaceuticals

REMODULIN is a prostacyclin mimetic formulated for SC or IV administration to treat PAH (WHO Group 1) and to diminish associated symptoms with exercise. It is included in patients with NYHA FC II–IV symptoms and etiologies of IPAH, HPAH, PAH associated with CTD, and PAH associated with congenital systemic-to-pulmonary shunts. It is also recommended for patients with PAH requiring transition from epoprostenol, as it diminishes the rate of clinical deterioration. United Therapeutics is currently conducting Phase I studies to develop a new prodrug called RemoPro (treprostinil) to enable SC delivery of treprostinil analog therapy without any site pain that is associated with SC REMODULIN (treprostinil).

 

Products detail in the report…

 

TYVASO (treprostinil): United Therapeutics

TYVASO is a drug-device combination therapy comprised of a dry powder formulation of treprostinil and a small, portable dry powder inhaler. It is a single-dose plastic cartridge filled with 1% treprostinil, a prostacyclin mimetic for administration by oral inhalation using the TYVASO DPI inhaler. TYVASO DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) inhalation powder product, which the FDA approved in 2014. DPI device represents a convenient option for the administration of treprostinil therapy. TYVASO was initially approved as an inhalation solution for oral inhalation using the TYVASO Inhalation System, which consisted of Optineb-ir, an ultrasonic, pulsed-delivery device.

 

Products detail in the report…

List of products to be continued in the report…

 

Pulmonary Arterial Hypertension Emerging Drugs

The potential drugs expected to launch in the forecast period include Sotatercept (MK-7962) (Merck), ralinepag (United Therapeutics), RT234 (vardenafil inhalation powder) (Respira Therapeutics), seralutinib (GB002) (Gossamer Bio), YUTREPIA (inhaled dry powder formulation of treprostinil) (Liquidia Technologies), TNX-201 (Tenax Therapeutics), and others.

 

Sotatercept (MK-7962): Merck

Sotatercept is an investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein designed to be a selective ligand trap for members of the TGF-beta superfamily to re-balance antiproliferative (BMPRII/Smad1/5/8-mediated) and pro-proliferative (ActRIIA/Smad2/3-mediated) signaling, which is a key molecular driver of PAH. Recently, Merck announced positive results of the Phase III STELLAR trial evaluating the safety and efficacy of Sotatercept as an add-on to stable background therapy for treating PAH (WHO Group 1). Additional Phase III trials evaluating Sotatercept in patients with PAH include ZENITH and HYPERION. Merck is also conducting Phase II trials to assess the safety and efficacy of Sotatercept in children with PAH.

 

Products detail in the report…

 

Ralinepag: United Therapeutics

Ralinepag is a novel, oral, selective, and potent prostacyclin receptor agonist being developed by United Therapeutics for treating PAH. In vitro studies indicate that Ralinepag has high binding affinity and selectivity at the human prostacyclin (IP) receptor. United Therapeutics is currently enrolling two Phase III studies of Ralinepag, ADVANCE OUTCOMES, and ADVANCE CAPACITY. Both of these studies are global, multicenter, placebo-controlled trials of patients on approved oral background PAH therapies.

 

Products detail in the report…

 

RT234 (vardenafil inhalation powder): Respira Therapeutics

RT234 is a first-in-class inhaled therapy intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue, the most commonly reported symptoms in PAH patients (Group 1 in the WHO’s classification of PH indications). RT234 is a drug-device combination of a capsule and the novel axial oscillating sphere (AOS) dry powder inhaler. Vardenafil is a dry powder; the inhaler is specifically designed to deliver this powdered drug to the lungs. Respira intends to pursue additional indications for RT234 in other WHO PH patient groups and is currently conducting Phase IIb trials (VIPAH-PRN 2B) to treat PAH.

 

Products detailed in the report…

 

Seralutinib (GB002) (Gossamer Bio)

Seralutinib is an inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor in development for the treatment of PAH. Seralutinib targets PDGFRa/ß, CSF1R, and c-KIT and upregulates BMPR2 protein expression; these pathways play important roles in PAH. It significantly reduces the right ventricular systolic pressure and mean pulmonary artery pressure. Recently, Gossamer Bio announced the topline results from the Phase II TORREY study, favoring seralutinib with enhanced effects in patients with more severe disease at baseline. Gossamer Bio had commenced investment in operational activities to enable the commencement of a registrational Phase III clinical program by the third quarter of 2023.

 

Products detailed in the report…

List of products to be continued in the report…

 

Pulmonary Arterial Hypertension Market Outlook

The current mainstay therapies to treat PAH act to dilate the pulmonary vasculature, decreasing pulmonary vascular resistance and secondarily improving right ventricular function, thereby improving functional capacity. The overall treatment goal is to improve survival, quality of life, exercise capacity, symptom burden, and clinical worsening, with risk stratification tools increasingly used to guide therapy and improve each of these elements. Current treatment recommendations weigh the use of multiple factors, including WHO FC, exercise ability, lab indices, and hemodynamic and echocardiographic variables to establish the overall severity of the disease and guide the intensity of therapy. Initial therapy choices and subsequent therapy changes are determined to achieve a low-risk category that helps improve overall survival and functional status in PAH.

 

The four drug classes (PDE5 inhibitors, sGC stimulators, ERAs, prostacyclin analog, and agonists) widely used for treating target three major signaling pathways, prostacyclin, endothelin, and nitric oxide, are responsible for PAH.  The marketed therapies approved for the treatment of PAH across various WHO Functional Classes (FC) include Johnson & Johnson/Nippon Shinyaku’s UPTRAVI (selexipag) and OPSUMIT (macitentan), United Therapeutics’ REMODULIN (treprostinil) (IV, SC), TYVASO (treprostinil, Inhaled), and ORENITRAM (treprostinil), Bayer/Merck’s ADEMPAS (riociguat). Other therapies which were approved but have their generics in the market include REVATIO (sildenafil), ADCIRCA (tadalafil), LETAIRIS/ VOLIBRIS (ambrisentan), VENTAVIS (iloprost), TRACLEER (Bosentan), BERAPROST (TRK-100), and VELETRI (epoprostenol).

 

Recently a combination therapy of LETAIRIS/ VOLIBRIS (ambrisentan) and ADCIRCA (tadalafil) also received approval. Most of these therapies are approved for adults except sildenafil, though trials are ongoing in the pediatric population for UPTRAVI, ADEMPAS, and OPSUMIT. Janssen Pharmaceuticals is also developing OPSUMIT with tadalafil as a fixed-dose combination formulation.

 

None of these drugs are curative and have side effects associated with their long-term use. The market has a thirst for therapies that address the shortcomings associated with the current treatment regime. Newer treatments with a novel mechanism of action are expected to enter the market and change the treatment and market regime.

 

According to DelveInsight, the overall dynamics of the Pulmonary Arterial Hypertension market is anticipated to change in the coming years owing to the expected launch of emerging therapies.

 

Key Findings

  • The market size of Pulmonary Arterial Hypertension in the seven major markets was approximately USD 4,871.0 million in 2021, which is further expected to increase by 2032.
  • The market size in the 7MM will increase at a CAGR of 3.6% due to increasing awareness of the disease.
  • Among the 7MM countries, the US accounted for the highest market size of Pulmonary Arterial Hypertension with approximately USD 3,848.1 million in 2021 which is likely to increase by 2032.
  • Among EU4 and the United Kingdom, Germany accounted for approximately USD 211.2 million in 2021, followed by France with approximately USD 169.1 million in the respective year, while Spain accounted for the lowest market with approximately USD 117.0 million in 2021.
  • Japan accounted for approximately USD 243.0 million in 2021, which is expected to increase by 2032.

 

The United States Market Outlook

This section provides the total Pulmonary Arterial Hypertension market size and market size by therapies (therapeutic and prophylactic) in the United States.

 

EU4 and the United Kingdom Market Outlook

The total Pulmonary Arterial Hypertension market size and market size by therapies (therapeutic and prophylactic) in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Pulmonary Arterial Hypertension market size and market size by therapies (therapeutic and prophylactic) in Japan are provided.

 

Pulmonary Arterial Hypertension Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Pulmonary Arterial Hypertension market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pulmonary Arterial Hypertension Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.

 

Pulmonary Arterial Hypertension Clinical Trial Development Activities

The Pulmonary Arterial Hypertension clinical trial report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Pulmonary Arterial Hypertension emerging therapies.

 

Reimbursement Scenario in Pulmonary Arterial Hypertension

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Pulmonary Arterial Hypertension market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Pulmonary Arterial Hypertension Market Report

  • The report covers a descriptive overview of Pulmonary Arterial Hypertension, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into Pulmonary Arterial Hypertension epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Pulmonary Arterial Hypertension is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Pulmonary Arterial Hypertension market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • Detailed Patient-Based Pulmonary Arterial Hypertension Market forecasting determines the trends shaping and driving the 7MM Pulmonary Arterial Hypertension market.

 

Pulmonary Arterial Hypertension Market Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Pulmonary Arterial Hypertension market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Pulmonary Arterial Hypertension. The launch of emerging therapies (therapeutic and prophylactic) will significantly impact the Pulmonary Arterial Hypertension market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed Pulmonary Arterial Hypertension clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Pulmonary Arterial Hypertension Report Insights

  • Patient-Based Pulmonary Arterial Hypertension Market Forecasting
  • Therapeutic Approaches
  • Pulmonary Arterial Hypertension Pipeline Analysis
  • Pulmonary Arterial Hypertension Market Size and Trends
  • Pulmonary Arterial Hypertension Market Opportunities
  • Impact of upcoming Therapies (therapeutic and prophylactic)

 

Pulmonary Arterial Hypertension Report Key Strengths

  • 11-Years Forecast
  • The 7MM Coverage
  • Pulmonary Arterial Hypertension Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

 

Pulmonary Arterial Hypertension Report Assessment

  • Current Treatment Practices
  • Pulmonary Arterial Hypertension Unmet Needs
  • Pulmonary Arterial Hypertension Pipeline Product Profiles
  • Pulmonary Arterial Hypertension Market Attractiveness
  • SWOT analysis

 

Key Questions

Pulmonary Arterial Hypertension Market Insights:

  • What was the Pulmonary Arterial Hypertension market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Pulmonary Arterial Hypertension total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Pulmonary Arterial Hypertension market size during the forecast period (2022–2032)?
  • At what CAGR, the Pulmonary Arterial Hypertension market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Pulmonary Arterial Hypertension market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Pulmonary Arterial Hypertension market growth till 2032 and what will be the resultant market size in the year 2032?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and Pulmonary Arterial Hypertension unmet needs?
  • What is the historical Pulmonary Arterial Hypertension patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • What would be the forecasted patient pool of Pulmonary Arterial Hypertension at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Pulmonary Arterial Hypertension?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Pulmonary Arterial Hypertension during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Pulmonary Arterial Hypertension along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Pulmonary Arterial Hypertension in the US and Europe?
  • What are the Pulmonary Arterial Hypertension marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Pulmonary Arterial Hypertension?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Pulmonary Arterial Hypertension?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to Pulmonary Arterial Hypertension therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Pulmonary Arterial Hypertension and their status?
  • What are the key designations that have been granted for the emerging therapies for Pulmonary Arterial Hypertension?
  • What is the 7MM historical and forecasted market for Pulmonary Arterial Hypertension?

 

Reasons to buy

  • The Patient-Based Pulmonary Arterial Hypertension Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving Pulmonary Arterial Hypertension.
  • To understand the future market competition in the Pulmonary Arterial Hypertension market.
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Pulmonary Arterial Hypertension market.
  • To understand the future market competition in the Pulmonary Arterial Hypertension market.

Frequently Asked Questions

What is the Pulmonary Arterial Hypertension?
Pulmonary arterial hypertension is a progressive disease of the lung vascular system, primarily affecting the small pulmonary arterioles. PH is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization.
Who are the leading companies in the Pulmonary Arterial Hypertension Market Landscape?
Some of the key players of Pulmonary Arterial Hypertension Market includes Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GSK, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, Bayer Group, Actelion Pharmaceuticals, Co Therix, Kaken Pharmaceutical, Sanofi-Aventis, Toray, Acceleron Pharma Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp & Dohme Corp., Insmed Incorporated, Pharmaosa Biopharma Inc., Bial (Portela C S.A.), Liquida Technologies, Inc., Cereno Scientific AB, and others.
What are the key strengths of Pulmonary Arterial Hypertension Market Report?
Key strengths of Pulmonary Arterial Hypertension Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers and Market Barriers.
Which country is expected to account for the most significant prevalent cases for Pulmonary Arterial Hypertension in the 7MM?
The US is expected to account for the highest Pulmonary Arterial Hypertension prevalent cases.

1. Key Insights

2. Pulmonary Arterial Hypertension Report Introduction

3. Pulmonary Arterial Hypertension Market Overview at a Glance

3.1. Market Share (%) Distribution of PAH in 2019

3.2. Market Share (%) Distribution of PAH in 2032

4. Methodology of PAH Epidemiology and Market

5. Executive Summary of PAH

6. Key Events

7. Disease Background and Overview

7.1. Introduction to PAH

7.2. Signs and Symptoms

7.3. Classification of PAH

7.3.1. WHO classification

7.3.2. Functional Classification of PAH

7.4. Etiology

7.5. Risk factors

7.6. Pathophysiology

7.6.1. Nitric oxide (NO) pathway

7.6.2. Prostacyclin–thromboxane A2 pathway

7.6.3. Endothelin-1 pathway

7.7. Diagnosis

7.8. Management and Treatment

7.9. Treatment Guidelines

7.9.1. American College of Chest Physicians (CHEST) Guidelines

7.9.2. European Society of Cardiology (ESC)/ the European Respiratory Society (ERS) Guidelines for the Treatment of Pulmonary Hypertension

8. Pulmonary Arterial Hypertension Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale: The 7MM

8.2.1. Total Prevalent Cases of PAH

8.2.2. Total Diagnosed Cases of PAH

8.2.3. Age-specific cases of PAH

8.2.4. Class-specific Cases of PAH

8.2.5. Gender-specific cases of PAH

8.2.6. Subtype-specific cases of PAH

8.3. Total Prevalent Cases of PAH in the 7MM

8.4. Total Diagnosed Cases of PAH in the 7MM

8.5. The US

8.5.1. Total Prevalent Cases of PAH in the US

8.5.2. Total Diagnosed Cases of PAH in the US

8.5.3. Age-specific Cases of PAH in the US

8.5.4. Class-specific Cases of PAH in the US

8.5.5. Gender-specific Cases of PAH in the US

8.5.6. Subtype-specific Cases of PAH in the US

8.6. EU4 and the UK

8.6.1. Total Prevalent Cases of PAH in EU4 and the UK

8.6.2. Total Diagnosed Cases of PAH in EU4 and the UK

8.6.3. Age-specific Cases of PAH in EU4 and the UK

8.6.4. Class-specific Cases of PAH in EU4 and the UK

8.6.5. Gender-specific Cases of PAH in EU4 and the UK

8.6.6. Subtype-specific Cases of PAH in EU4 and the UK

8.6.7. Germany

8.6.7.1. Total Prevalent Cases of PAH in Germany

8.6.7.2. Total Diagnosed Cases of PAH in Germany

8.6.7.3. Age-specific Cases of PAH in Germany

8.6.7.4. Class-specific Cases of PAH in Germany

8.6.7.5. Gender-specific Cases of PAH in Germany

8.6.7.6. Subtype-specific Cases of PAH in Germany

8.6.8. France

8.6.8.1. Total Prevalent Cases of PAH in France

8.6.8.2. Total Diagnosed Cases of PAH in France

8.6.8.3. Age-specific Cases of PAH in France

8.6.8.4. Class-specific Cases of PAH in France

8.6.8.5. Gender-specific Cases of PAH in France

8.6.8.6. Subtype-specific Cases of PAH in France

8.6.9. Italy

8.6.9.1. Total Prevalent Cases of PAH in Italy

8.6.9.2. Total Diagnosed Cases of PAH in Italy

8.6.9.3. Age-specific Cases of PAH in Italy

8.6.9.4. Class-specific Cases of PAH in Italy

8.6.9.5. Gender-specific Cases of PAH in Italy

8.6.9.6. Subtype-specific Cases of PAH in Italy

8.6.10. Spain

8.6.10.1. Total Prevalent Cases of PAH in Spain

8.6.10.2. Total Diagnosed Cases of PAH in Spain

8.6.10.3. Age-specific Cases of PAH in Spain

8.6.10.4. Class-specific Cases of PAH in Spain

8.6.10.5. Gender-specific Cases of PAH in Spain

8.6.10.6. Subtype-specific Cases of PAH in Spain

8.6.11. The UK

8.6.11.1. Total Prevalent Cases of PAH in the UK

8.6.11.2. Total Diagnosed Cases of PAH in the UK

8.6.11.3. Age-specific Cases of PAH in the UK

8.6.11.4. Class-specific Cases of PAH in the UK

8.6.11.5. Gender-specific Cases of PAH in the UK

8.6.11.6. Subtype-specific Cases of PAH in the UK

8.7. Japan

8.7.1. Total Prevalent Cases of PAH in Japan

8.7.2. Total Diagnosed Cases of PAH in Japan

8.7.3. Age-specific Cases of PAH in Japan

8.7.4. Class-specific Cases of PAH in Japan

8.7.5. Gender-specific Cases of PAH in Japan

8.7.6. Subtype-specific Cases of PAH in Japan

9. Patient Journey

10. Marketed Drugs

10.1. Key Cross Competition

10.2. UPTRAVI (selexipag): Johnson & Johnson/Nippon Shinyaku

10.2.1. Product description

10.2.2. Regulatory milestone

10.2.3. Other development activities

10.2.4. Clinical development

10.2.5. Clinical trial information

10.2.6. Safety and efficacy

10.2.7. Product profile

10.3. REMODULIN/ TREPROST (treprostinil): United Therapeutics/ Mochida Pharmaceutical

10.3.1. Product description

10.3.2. Regulatory milestone

10.3.3. Other development activities

10.3.4. Safety and efficacy

10.3.5. Product profile

10.4. TYVASO (treprostinil): United Therapeutics

10.4.1. Product description

10.4.2. Regulatory milestone

10.4.3. Other development activities

10.4.4. Clinical trial information

10.4.5. Safety and efficacy

10.4.6. Product profile

10.5. ORENITRAM (treprostinil): United Therapeutics

10.5.1. Drug description

10.5.2. Regulatory milestone

10.5.3. Other development activities

10.5.4. Clinical trial information

10.5.5. Safety and efficacy

10.5.6. Product profile

10.6. ADEMPAS (riociguat): Bayer/Merck

10.6.1. Product description

10.6.2. Regulatory milestone

10.6.3. Other development activities

10.6.4. Clinical trial information

10.6.5. Safety and efficacy

10.6.6. Product profile

10.7. OPSUMIT (macitentan): Johnson & Johnson/Nippon Shinyaku

10.7.1. Drug description

10.7.2. Regulatory milestone

10.7.3. Other development activities

10.7.4. Clinical development

10.7.5. Clinical trial information

10.7.6. Safety and efficacy

10.7.7. Product profile

11. Pulmonary Arterial Hypertension Emerging Drugs

11.1. Key Cross Competition

11.2. Sotatercept (MK-7962): Merck

11.2.1. Product description

11.2.2. Other development activities

11.2.3. Clinical development

11.2.4. Clinical trial information

11.2.5. Safety and efficacy

11.2.6. Product profile

11.2.7. Analysts’ views

11.3. Ralinepag: United Therapeutics

11.3.1. Product description

11.3.2. Other development activities

11.3.3. Clinical development

11.3.4. Clinical trial information

11.3.5. Safety and efficacy

11.3.6. Product profile

11.3.7. Analysts’ views

11.4. YUTREPIA (treprostinil): Liquida Technologies

11.4.1. Product description

11.4.2. Other development activities

11.4.3. Clinical development

11.4.4. Clinical trial information

11.4.5. Safety and efficacy

11.4.6. Product profile

11.4.7. Analysts’ views

11.5. TNX-201: Tenax Therapeutics

11.5.1. Product description

11.5.2. Other development activities

11.5.3. Clinical development

11.5.4. Clinical trial information

11.5.5. Safety and efficacy

11.5.6. Product profile

11.5.7. Analysts’ views

11.6. RT234 (vardenafil inhalation powder): Respira Therapeutics

11.6.1. Product description

11.6.2. Other development activities

11.6.3. Clinical development

11.6.4. Clinical trial information

11.6.5. Safety and efficacy

11.6.6. Product profile

11.6.7. Analysts’ views

11.7. Seralutinib (GB002): Gossamer Bio

11.7.1. Product description

11.7.2. Other development activities

11.7.3. Clinical development

11.7.4. Clinical trial information

11.7.5. Safety and efficacy

11.7.6. Product profile

11.7.7. Analysts’ views

11.8. L606 (liposomal treprostinil): Pharmosa Biopharma

11.8.1. Product description

11.8.2. Clinical development

11.8.3. Clinical trial information

11.8.4. Safety and efficacy

11.8.5. Product profile

11.8.6. Analysts’ views

11.9. MK-5475: Merck Sharp & Dohme

11.9.1. Product description

11.9.2. Clinical development

11.9.3. Clinical trial information

11.9.4. Safety and efficacy

11.9.5. Product profile

11.10. AV-101: Aerovate Therapeutics

11.10.1. Product description

11.10.2. Other development activities

11.10.3. Clinical development

11.10.4. Clinical trial information

11.10.5. Safety and efficacy

11.10.6. Product profile

11.11. Treprostinil Palmitil: Insmed

11.11.1. Product description

11.11.2. Other development activities

11.11.3. Clinical development

11.11.4. Clinical trial information

11.11.5. Safety and Efficacy

11.11.6. Product profile

11.12. LTP001: Novartis

11.12.1. Product description

11.12.2. Clinical development

11.12.3. Clinical trial information

11.12.4. Product profile

11.12.5. Analysts’ views

11.13. Oral Ifetroban: Cumberland Pharmaceuticals

11.13.1. Product description

11.13.2. Other development activities

11.13.3. Clinical development

11.13.4. Clinical trial information

11.13.5. Product profile

11.13.6. Analysts’ views

11.14. Rodatristat Ethyl: Enzyvant Therapeutics

11.14.1. Product description

11.14.2. Other development activities

11.14.3. Clinical development

11.14.4. Clinical trial information

11.14.5. Safety and efficacy

11.14.6. Product profile

11.14.7. Analysts’ views

11.15. CS1: Cereno Scientific

11.15.1. Product description

11.15.2. Other development activities

11.15.3. Clinical development

11.15.4. Clinical trial information

11.15.5. Product profile

11.16. Olaparib: AstraZeneca

11.16.1. Product description

11.16.2. Clinical development

11.16.3. Clinical trial information

11.16.4. Product profile

11.16.5. Analysts’ views

11.17. PB1046: PhaseBio Pharmaceutical

11.17.1. Product description

11.17.2. Other development activities

11.17.3. Clinical development

11.17.4. Clinical trial information

11.17.5. Product profile

11.17.6. Analysts’ views

12. Pulmonary Arterial Hypertension Market Analysis

12.1. Key Findings

12.2. Key Market Forecast Assumptions

12.3. Market Outlook

12.4. Attribute Analysis

12.5. Market Size of PAH in the 7MM

12.6. Market Size of PAH by Therapies in the 7MM

12.7. Market Size of PAH in the US

12.7.1. Total market size of PAH

12.7.2. Market size of PAH by therapies

12.8. Market Size of PAH in EU4 and the UK

12.8.1. Total market size of PAH

12.8.2. Market size of PAH by therapies

12.8.3. Germany

12.8.3.1. Total market size of PAH

12.8.3.2. Market size of PAH by therapies

12.8.4. France

12.8.4.1. Total market size of PAH

12.8.4.2. Market size of PAH by therapies

12.8.5. Italy

12.8.5.1. Total market size of PAH

12.8.5.2. Market size of PAH by therapies

12.8.6. Spain

12.8.6.1. Total market size of PAH

12.8.6.2. Market size of PAH by therapies

12.8.7. The UK

12.8.7.1. Total market size of PAH

12.8.7.2. Market size of PAH by therapies

12.9. Market Size of PAH in Japan

12.9.1. Total market size of PAH

12.9.2. Market size of PAH by therapies

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Pulmonary Arterial Hypertension Unmet Needs

16 Pulmonary Arterial Hypertension Market Access and Reimbursement

16.1. The United States

16.1.1. Center for Medicare & Medicaid Services (CMS)

16.2. EU4 and the UK

16.2.1. Germany

16.2.2. France

16.2.3. Italy

16.2.4. Spain

16.2.5. The United Kingdom

16.3. Japan

16.3.1. MHLW

17. Appendix

17.1. Bibliography

17.2. Acronyms and Abbreviations

17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of PAH Market and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Clinical features

Table 4: Clinical Features

Table 5: Total Prevalent Cases of PAH in the 7MM (2019–2032)

Table 6: Total Diagnosed Cases of PAH in the 7MM (2019–2032)

Table 7: Total Prevalent Cases of PAH in the US (2019–2032)

Table 8: Total Diagnosed Cases of PAH in the US (2019–2032)

Table 9: Age-specific Cases of PAH in the US (2019–2032)

Table 10: Class-specific Cases of PAH in the US (2019–2032)

Table 11: Gender-specific Cases of PAH in the US (2019–2032)

Table 12: Subtype-specific Cases of PAH in the US (2019–2032)

Table 13: Total Prevalent Cases of PAH in EU4 and the UK (2019–2032)

Table 14: Total Diagnosed Cases of PAH in EU4 and the UK (2019–2032)

Table 15: Age-specific Cases of PAH in EU4 and the UK (2019–2032)

Table 16: Class-specific Cases of PAH in EU4 and the UK (2019–2032)

Table 17: Gender-specific Cases of PAH in EU4 and the UK (2019–2032)

Table 18: Subtype-specific Cases of PAH in EU4 and the UK (2019–2032)

Table 19: Total Prevalent Cases of PAH in Germany (2019–2032)

Table 20: Total Diagnosed Cases of PAH in Germany (2019–2032)

Table 21: Age-specific Cases of PAH in Germany (2019–2032)

Table 22: Class-specific Cases of PAH in Germany (2019–2032)

Table 23: Gender-specific Cases of PAH in Germany (2019–2032)

Table 24: Subtype-specific Cases of PAH in Germany(2019–2032)

Table 25: Total Prevalent Cases of PAH in France (2019–2032)

Table 26: Total Diagnosed Cases of PAH in France (2019–2032)

Table 27: Age-specific Cases of PAH in France (2019–2032)

Table 28: Class-specific Cases of PAH in France (2019–2032)

Table 29: Gender-specific Cases of PAH in France (2019–2032)

Table 30: Subtype-specific Cases of PAH in France (2019–2032)

Table 31: Total Prevalent Cases of PAH in Italy (2019–2032)

Table 32: Total Diagnosed Cases of PAH in Italy (2019–2032)

Table 33: Age-specific Cases of PAH in Italy (2019–2032)

Table 34: Class-specific Cases of PAH in Italy (2019–2032)

Table 35: Gender-specific Cases of PAH in Italy (2019–2032)

Table 36: Subtype-specific Cases of PAH in Italy (2019–2032)

Table 37: Total Prevalent Cases of PAH in Spain (2019–2032)

Table 38: Total Diagnosed Cases of PAH in Spain (2019–2032)

Table 39: Age-specific Cases of PAH in Spain (2019–2032)

Table 40: Class-specific Cases of PAH in Spain (2019–2032)

Table 41: Gender-specific Cases of PAH in Spain (2019–2032)

Table 42: Subtype-specific Cases of PAH in Spain (2019–2032)

Table 43: Total Prevalent Cases of PAH in the UK (2019–2032)

Table 44: Total Diagnosed Cases of PAH in the UK (2019–2032)

Table 45: Age-specific Cases of PAH in the UK (2019–2032)

Table 46: Class-specific Cases of PAH in the UK (2019–2032)

Table 47: Gender-specific Cases of PAH in the UK (2019–2032)

Table 48: Subtype-specific Cases of PAH in the UK (2019–2032)

Table 49: Total Prevalent Cases of PAH in Japan (2019–2032)

Table 50: Total Diagnosed Cases of PAH in Japan (2019–2032)

Table 51: Age-specific Cases of PAH in Japan (2019–2032)

Table 52: Class-specific Cases of PAH in Japan (2019–2032)

Table 53: Gender-specific Cases of PAH in Japan (2019–2032)

Table 54: Subtype-specific Cases of PAH in Japan (2019–2032)

Table 55: Comparison of Marketed Drugs

Table 56: UPTRAVI (selexipag), Clinical Trial Description, 2022

Table 57: TYVASO DPI, Clinical Trial Description, 2022

Table 58: ORENITRAM (treprostinil), Clinical Trial Description, 2022

Table 59: ADEMPAS (riociguat), Clinical Trial Description, 2022

Table 60: OPSUMIT (macitentan), Clinical Trial Description, 2022

Table 61: Comparison of Emerging Drugs Under Development

Table 62: Sotatercept (MK-7962), Clinical Trial Description, 2022

Table 63: Ralinepag, Clinical Trial Description, 2022

Table 64: YUTREPIA (treprostinil), Clinical Trial Description, 2022

Table 65: TNX-201, Clinical Trial Description, 2022

Table 66: RT234, Clinical Trial Description, 2022

Table 67: Seralutinib (GB002), Clinical Trial Description, 2022

Table 68: L606, Clinical Trial Description, 2022

Table 69: MK-5475, Clinical Trial Description, 2022

Table 70: AV-101, Clinical Trial Description, 2022

Table 71: Treprostinil Palmitil, Clinical Trial Description, 2022

Table 72: LTP001, Clinical Trial Description, 2022

Table 73: Oral Ifetroban, Clinical Trial Description, 2022

Table 74: Rodatristat Ethyl, Clinical Trial Description, 2022

Table 75: CS1, Clinical Trial Description, 2022

Table 76: Olaparib, Clinical Trial Description, 2022

Table 77: PB1046, Clinical Trial Description, 2022

Table 78: Key Market Forecast Assumptions for Sotatercept (MK-7962)

Table 79: Key Market Forecast Assumptions for ralinepag

Table 80: Key Market Forecast Assumptions for RT234 (vardenafil)

Table 81: Key Market Forecast Assumptions for seralutinib (GB002)

Table 82: Key Market Forecast Assumptions for YUTREPIA (inhaled treprostinil)

Table 83: Key Market Forecast Assumptions for TNX-201

Table 84: Market Size of PAH in the 7MM, in USD million (2019–2032)

Table 85: Market Size of PAH by Therapies in the 7MM, in USD million (2019–2032)

Table 86: Market Size of PAH in the US, in USD million (2019–2032)

Table 87: Market Size of PAH by Therapies in the US, in USD million (2019–2032)

Table 88: Market Size of PAH in EU4 and the UK, in USD million (2019–2032)

Table 89: Market Size of PAH in Germany, in USD million (2019–2032)

Table 90: Market Size of PAH by Therapies in Germany, in USD million (2019–2032)

Table 91: Market Size of PAH in France, in USD million (2019–2032)

Table 92: Market Size of PAH by Therapies in France, in USD million (2019–2032)

Table 93: Market Size of PAH in Italy, in USD million (2019–2032)

Table 94: Market Size of PAH by Therapies in Italy, in USD million (2019–2032)

Table 95: Market Size of PAH in Spain, in USD million (2019–2032)

Table 96: Market Size of PAH by Therapies in Spain, in USD million (2019–2032)

Table 97: Market Size of PAH in the UK, in USD million (2019–2032)

Table 98: Market Size of PAH by Therapies in the UK, in USD million (2019–2032)

Table 99: Market Size of PAH by Therapies in EU4 and the UK, in USD million (2019–2032)

Table 100: Market Size of PAH in Japan, in USD million (2019–2032)

Table 101: Market Size of PAH by Therapies in Japan, in USD million (2019–2032)

List of Figures

Figure 1: Symptoms of PAH

Figure 2: Classification of PAH

Figure 3: Functional Classification of PAH

Figure 4: Risk Factors of PAH

Figure 5: Pathophysiology of PAH

Figure 6: Pathophysiology of PAH

Figure 7: Diagnostic algorithm for PAH

Figure 8: Treatment Options for PAH

Figure 9: Treatment Algorithm for PAH

Figure 10: Total Prevalent Cases of PAH in the 7MM (2019–2032)

Figure 11: Total Diagnosed Cases of PAH in the 7MM (2019–2032)

Figure 12: Total Prevalent Cases of PAH in the US (2019–2032)

Figure 13: Total Diagnosed Cases of PAH in the US (2019–2032)

Figure 14: Age-specific Cases of PAH in the US (2019–2032)

Figure 15: Class-specific Cases of PAH in the US (2019–2032)

Figure 16: Gender-specific Cases of PAH in the US (2019–2032)

Figure 17: Subtype-specific Cases of PAH in the US (2019–2032)

Figure 18: Total Prevalent Cases of PAH in EU4 and the UK (2019–2032)

Figure 19: Total Diagnosed Cases of PAH in EU4 and the UK (2019–2032)

Figure 20: Age-specific Cases of PAH in EU4 and the UK (2019–2032)

Figure 21: Class-specific Cases of PAH in EU4 and the UK (2019–2032)

Figure 22: Gender-specific Cases of PAH in EU4 and the UK (2019–2032)

Figure 23: Subtype-specific Cases of PAH in EU4 and the UK (2019–2032)

Figure 24: Total Prevalent Cases of PAH in Germany (2019–2032)

Figure 25: Total Diagnosed Cases of PAH in Germany (2019–2032)

Figure 26: Age-specific Cases of PAH in Germany (2019–2032)

Figure 27: Class-specific Cases of PAH in Germany (2019–2032)

Figure 28: Gender-specific Cases of PAH in Germany (2019–2032)

Figure 29: Subtype-specific Cases of PAH in Germany(2019–2032)

Figure 30: Total Prevalent Cases of PAH in France (2019–2032)

Figure 31: Total Diagnosed Cases of PAH in France (2019–2032)

Figure 32: Age-specific Cases of PAH in France (2019–2032)

Figure 33: Class-specific Cases of PAH in France (2019–2032)

Figure 34: Gender-specific Cases of PAH in France (2019–2032)

Figure 35: Subtype-specific Cases of PAH in France (2019–2032)

Figure 36: Total Prevalent Cases of PAH in Italy (2019–2032)

Figure 37: Total Diagnosed Cases of PAH in Italy (2019–2032)

Figure 38: Age-specific Cases of PAH in Italy (2019–2032)

Figure 39: Class-specific Cases of PAH in Italy (2019–2032)

Figure 40: Gender-specific Cases of PAH in Italy (2019–2032)

Figure 41: Subtype-specific Cases of PAH in Italy (2019–2032)

Figure 42: Total Prevalent Cases of PAH in Spain (2019–2032)

Figure 43: Total Diagnosed Cases of PAH in Spain (2019–2032)

Figure 44: Age-specific Cases of PAH in Spain (2019–2032)

Figure 45: Class-specific Cases of PAH in Spain (2019–2032)

Figure 46: Gender-specific Cases of PAH in Spain (2019–2032)

Figure 47: Subtype-specific Cases of PAH in Spain (2019–2032)

Figure 48: Total Prevalent Cases of PAH in the UK (2019–2032)

Figure 49: Total Diagnosed Cases of PAH in the UK (2019–2032)

Figure 50: Age-specific Cases of PAH in the UK (2019–2032)

Figure 51: Class-specific Cases of PAH in the UK (2019–2032)

Figure 52: Gender-specific Cases of PAH in the UK (2019–2032)

Figure 53: Subtype-specific Cases of PAH in the UK (2019–2032)

Figure 54: Total Prevalent Cases of PAH in Japan (2019–2032)

Figure 55: Total Diagnosed Cases of PAH in Japan (2019–2032)

Figure 56: Age-specific Cases of PAH in Japan (2019–2032)

Figure 57: Class-specific Cases of PAH in Japan (2019–2032)

Figure 58: Gender-specific Cases of PAH in Japan (2019–2032)

Figure 59: Subtype-specific Cases of PAH in Japan (2019–2032)

Figure 60: Patient Journey

Figure 61: Market Size of PAH in the 7MM, in USD million (2019–2032)

Figure 62: Market Size of PAH by Therapies in the 7MM, in USD million (2019–2032)

Figure 63: Market Size of PAH in the US, in USD million (2019–2032)

Figure 64: Market Size of PAH by Therapies in the US, in USD million (2019–2032)

Figure 65: Market Size of PAH in EU4 and the UK, in USD million (2019–2032)

Figure 66: Market Size of PAH in Germany, in USD million (2019–2032)

Figure 67: Market Size of PAH by Therapies in Germany, in USD million (2019–2032)

Figure 68: Market Size of PAH in France, in USD million (2019–2032)

Figure 69: Market Size of PAH by Therapies in France, in USD million (2019–2032)

Figure 70: Market Size of PAH in Italy, in USD million (2019–2032)

Figure 71: Market Size of PAH by Therapies in Italy, in USD million (2019–2032)

Figure 72: Market Size of PAH in Spain, in USD million (2019–2032)

Figure 73: Market Size of PAH by Therapies in Spain, in USD million (2019–2032)

Figure 74: Market Size of PAH in the UK, in USD million (2019–2032)

Figure 75: Market Size of PAH by Therapies in the UK, in USD million (2019–2032)

Figure 76: Market Size of PAH by Therapies in EU4 and the UK, in USD million (2019–2032)

Figure 77: Market Size of PAH in Japan, in USD million (2019–2032)

Figure 78: Market Size of PAH by Therapies in Japan, in USD million (2019–2032)

Figure 79: Pulmonary Arterial Hypertension Unmet Needs

Figure 80: Health Technology Assessment

Figure 81: Reimbursement Process in Germany

Figure 82: Reimbursement Process in France

Figure 83: Reimbursement Process in Italy

Figure 84: Reimbursement Process in Spain

Figure 85: Reimbursement Process in the United Kingdom

Figure 86: Reimbursement Process in Japan

Merck
United Therapeutics
Liquida Technologies
Tenax Therapeutics
Respira Therapeutics
Gossamer Bio
Pharmosa Biopharma
Aerovate Therapeutics
Insmed
Novartis
Cumberland Pharmaceuticals
Enzyvant Therapeutics
AstraZeneca
Cereno Scientific
PhaseBio Pharmaceutical

 

Forward to Friend

Need A Quote